Myokardia
South San Francisco, US · Founded 2012 · Delaware corporation · 3 known investors
Biotech
Founders & leadership
TA
Tassos Anastasios GianakakosExecutive
Board
KS
CH
MP
Mark PerryBoard director
KB
Katherine BowdishBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$56M disclosed across 2 rounds · 2014–2015
▶$46MraisedApr 2015 · 9 investors · BiotechnologyRule 506(b)
▶$46MraisedApr 2015 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin StarrDirector
- Charles HomcyDirector
- Mark PerryDirector
- Katherine BowdishDirector
- Tassos Anastasios GianakakosExecutive Officer, Director
- Offering amount
- $46M
- Amount sold
- $46M
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$10MraisedAug 2014 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedAug 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tassos Anastasios GianakakosExecutive Officer, Director
- Charles HomcyDirector
- Kevin StarrDirector
- Mark PerryDirector
- Katherine BowdishDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Myokardia's investors?
- Myokardia's investors include Foresite Capital, Khosla Ventures, Third Rock Ventures.
- How much funding has Myokardia raised?
- Myokardia has disclosed $56M raised across 2 rounds.
- Where is Myokardia headquartered?
- Myokardia is headquartered in South San Francisco, US.